

[Daunorubicin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01DB02](#)

EMLc

Indication

Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: [2A60.0](#)

INN

Daunorubicin

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection ; 20 mg in vial (as hydrochloride) powder for injection ; 2 mg per mL in vial (as hydrochloride) ; 5 mg per mL in vial (as hydrochloride)

EML status history

First added in 1999 ([TRS 895](#))

Changed in 2002 ([TRS 914](#))

Changed in 2007 ([TRS 950](#))

Changed in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Daunorubicin](#)

DrugBank

[Daunorubicin](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.